Brendan Reardon
Overview
Explore the profile of Brendan Reardon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
2116
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tarantino G, Ricker C, Wang A, Ge W, Aprati T, Huang A, et al.
Sci Adv
. 2024 Nov;
10(48):eadp4670.
PMID: 39602539
The introduction of immune checkpoint blockade (ICB) has markedly improved outcomes for advanced melanoma. However, many patients develop resistance through unknown mechanisms. While combination ICB has improved response rate and...
2.
Sehgal K, Pappa T, Shin K, Schiantarelli J, Liu M, Ricker C, et al.
JAMA Oncol
. 2024 Oct;
10(12):1663-1671.
PMID: 39446365
Importance: Aggressive thyroid carcinoma, including radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), and anaplastic thyroid carcinoma (ATC), are associated with significant morbidity and mortality and have...
3.
Conway J, Gillani R, Crowdis J, Reardon B, Park J, Han S, et al.
J Clin Invest
. 2024 May;
134(13).
PMID: 38758740
The diversity of structural variants (SVs) in melanoma and how they impact oncogenesis are incompletely known. We performed harmonized analysis of SVs across melanoma histologic and genomic subtypes, and we...
4.
Han S, Camp S, Chu H, Collins R, Gillani R, Park J, et al.
Eur Urol Open Sci
. 2024 Mar;
62:107-122.
PMID: 38496821
Background And Objective: Previous germline studies on renal cell carcinoma (RCC) have usually pooled clear and non-clear cell RCCs and have not adequately accounted for population stratification, which might have...
5.
Huffman B, Singh H, Ali L, Horick N, Wang S, Hoffman M, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38272561
Background: Recent trials suggest that programmed cell death 1 (PD-1)-directed immunotherapy may be beneficial for some patients with anal squamous cell carcinoma and biomarkers predictive of response are greatly needed....
6.
Han S, Camp S, Chu H, Collins R, Gillani R, Park J, et al.
medRxiv
. 2023 Jan;
PMID: 36712083
Importance: RCC encompasses a set of histologically distinct cancers with a high estimated genetic heritability, of which only a portion is currently explained. Previous rare germline variant studies in RCC...
7.
Schiantarelli J, Pappa T, Conway J, Crowdis J, Reardon B, Dietlein F, et al.
JCO Precis Oncol
. 2022 Sep;
6:e2200183.
PMID: 36075011
No abstract available.
8.
Reardon B, Moore N, Moore N, Kofman E, AlDubayan S, Cheung A, et al.
Nat Cancer
. 2022 Feb;
2(10):1102-1112.
PMID: 35121878
Tumor molecular profiling of single gene-variant ('first-order') genomic alterations informs potential therapeutic approaches. Interactions between such first-order events and global molecular features (for example, mutational signatures) are increasingly associated with...
9.
Mossanen M, Carvalho F, Muralidhar V, Preston M, Reardon B, Conway J, et al.
Eur Urol
. 2021 Dec;
81(5):466-473.
PMID: 34953602
Background: Muscle-invasive bladder cancer (MIBC) is a rare but serious event following definitive radiation for prostate cancer. Radiation-associated MIBC (RA-MIBC) can be difficult to manage given the challenges of delivering...
10.
Keenan T, Guerriero J, Barroso-Sousa R, Li T, OMeara T, Giobbie-Hurder A, et al.
Nat Commun
. 2021 Sep;
12(1):5563.
PMID: 34548479
Immune checkpoint inhibitors (ICIs) have minimal therapeutic effect in hormone receptor-positive (HR+ ) breast cancer. We present final overall survival (OS) results (n = 88) from a randomized phase 2...